DMCA
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
| Venue: | J Cell Biol |
| Citations: | 34 - 4 self |
BibTeX
@ARTICLE{Bajou_theplasminogen,
author = {Khalid Bajou and Véronique Masson and Robert D. Gerard and Petra M. Schmitt and Valérie Albert and Michael Praus and Leif R. Lund and Thomas L. Fr and Nils Brunner and Keld Dano and Norbert E. Fusenig and Ulrich Weidle and Geert Carmeliet and David Loskutoff and Desiré Collen and Peter Carmeliet and Jean Michel Foidart and Agnès Noël},
title = {The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies},
journal = {J Cell Biol},
year = {},
pages = {152--777}
}
Share
 |
 |
 |
 |
||
OpenURL
Abstract
Abstract. The plasminogen (Plg)/plasminogen activator (PA) system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumor cell migration. Consequently, urokinase-type PA (uPA)/plasmin antagonists are currently being developed for suppression of tumor growth and angiogenesis. Paradoxically, however, high levels of PA inhibitor 1 (PAI-1) are predictive of a poor prognosis for survival of patients with cancer. We demonstrated previously that PAI-1 promoted tumor angiogenesis, but by an unresolved mechanism. We anticipated that PAI-1 facilitated endothelial cell migration via its known interaction with vitronectin (VN) and integrins. However, using adenoviral gene transfer of PAI-1 mutants, we observed that PAI-1 promoted tumor angiogenesis,
Keyphrases
plasminogen activator inhibitor pai-1 antiangiogenic strategy vivo tumor vascularization tumor angiogenesis pai-1 mutant poor prognosis high level tumor cell migration plasminogen activator plasmin antagonist extracellular matrix degradation adenoviral gene transfer key role tumor growth urokinase-type pa pa inhibitor endothelial cell migration unresolved mechanism cancer progression
